FundraiseDonate
Explainers

From ideas to saving lives: why research takes time 

January 07, 2026

Are you over the confusing and often misleading information filling social media feeds? Finding it hard to sort fact from fiction? 

Welcome to All Over It: stay smart in the era of misinformation. This is the first in a series of articles from the Ovarian Cancer Research Foundation (OCRF), designed to help us non-scientists take a look under the hood of the medical research process. With so much conflicting (and often dodgy) information circulating on social media, our expert team has put together some savvy but simple insights to help you stay smart in this era of misinformation.  

First up, we look at the real-world path to a ‘breakthrough’ 

We know that medical research saves lives — but those breakthroughs you see on the news don’t happen overnight. Every ‘breakthrough’ begins as an idea from a qualified researcher and must move through years of careful testing, safety checks, and real-world evaluation before it can help a patient. This isn’t inefficiency — it’s what keeps people safe and medicine as effective as possible. But why does it take so long? What is the process? Why is ovarian cancer research especially challenging? 

The OCRF recognises that for the ovarian cancer community, time is one of the most precious things, and waiting for progress can feel frustrating. That’s exactly why the OCRF works to remove barriers wherever possible, funding and working with researchers and other organisations to strengthen systems that help discoveries move forward faster. 

Understanding ovarian cancer's complexity: what researchers are up against

Why ovarian cancer is so complex — and why research matters 

 Ovarian cancer isn’t just one disease. In fact, it’s more than 30 different types, each with its own ‘personality’ — behaving, growing, and responding to treatment in unique ways. That means a breakthrough that works for one type might not work for another, which makes finding universal solutions a big challenge. 

No two ovarian cancers are exactly alike 

 Even when two people have the same subtype of ovarian cancer, their tumours can act very differently. Scientists call this heterogeneity — basically, it means “lots of variation”. 

  • Variation between people: Two women with the same diagnosis can have tumours with totally different genetic makeups. 
  • Variation within one person: A single tumour can actually be made up of many groups of cancer cells, each with its own characteristics. 

This variety makes ovarian cancer really tricky to detect and treat. There is no early detection test, and it’s hard to develop a one-size-fits-all test because different subtypes don’t always show the same biomarkers — the telltale flags that doctors and scientists look for in blood or tissue. Even when treatment starts working, it might only kill some groups of cancer cells while others survive and keep growing. 

Why the immune system struggles to fight back 

Normally, your immune cells act like bodyguards — spotting and attacking anything that doesn’t belong. But many ovarian cancers find ways to hide from them. Some create a kind of “no-go zone” that keeps immune cells out, or switches them off if they try to get in. This helps explain why immunotherapies (treatments that boost your immune system to fight cancer) haven’t yet worked as well for ovarian cancer as they have for other types. 

Why early detection of ovarian cancer is so hard 

One of the biggest challenges is that ovarian cancer often starts in the fallopian tubes, not the ovaries. It quietly develops there long before any symptoms show up. Tiny clusters of cancer cells can then move to the ovaries and beyond. Because this happens so early and without clear signs, doctors rarely find ovarian cancer while it’s still in the fallopian tubes. 

In addition, the diversity of disease means it’s unlikely there will be a single blood test or marker that can catch every case. That’s why researchers are working to identify the best combination of biomarkers to help detect ovarian cancers earlier and more accurately. 

The path forward

This complexity makes ovarian cancer one of the toughest cancers to study and treat — but it also means every research discovery teaches scientists something new. Step by step, with the support of organisations like OCRF, they’re figuring out how to target the right treatments for the right people, which is how breakthroughs happen.

The research pipeline— why each stage takes time

Medical research follows a careful, step-by-step pathway designed to ensure that new tests and treatments are truly safe and effective for patients.  Interestingly, the process looks different depending on whether researchers are developing: 

  • tests to find and/or diagnose disease early 
  • New therapies and treatments such as drugs and medications 

Understanding the difference helps explain why research takes years, sometimes decades. 

Developing cancer detection tests 

Developing an early detection test to find preliminary signs of cancer before it has spread is not easy – especially when a disease is as diverse and complex as ovarian cancer.  

The test must:  

  • detect cancers accurately,  
  • detect them early enough,  
  • not cause harm (such as false positives, which suggest that someone has cancer when they don’t).  

To become a screening test, suitable for wide use (such as mammograms, prostate cancer tests and cervical cancer screening), a test must also: 

  • work reliably and cost-effectively across large, diverse populations, and  
  • actually improve outcomes such as survival rates, at a population level. 

Early detection screening research requires large, long-term studies in diverse groups of people and retesting or validating across different hospitals and populations. This can be a slow and expensive process. 

Treatment (drug) research 

Developing drug treatments follows a more defined pathway, using phased clinical trials (Phase I, II, III). Each stage is highly regulated, costly and time-intensive, with strict safety and ethical requirements. 

Both research pathways share the same early stages (discovery and validation) but differ when they reach trials. 

Stages and timeline of research pathways:

This is where ideas begin. Researchers study the biology of ovarian cancer, including genes, proteins, cells, immune interactions and the environment around the tumour. Any of these factors can become potential ways to identify ovarian cancer (diagnostic) or ways to target and treat it.

Why it takes time:

  • Biology is messy and rarely straightforward— unexpected discoveries often raise new questions.
  • Experiments need to be repeated many times to be sure the results are real, not accidental or random.
  • Scientists also write about their findings and send them to other experts to check (this is called peer-review), which is slow, and it can take months to have findings published.
  • Money to complete research comes from funding rounds or grants (often a grant lasts 1-3 years), so scientists often have to take time to write grants and apply for funding.

Timeline: approx 3-10+ years

Scientists test whether a discovery is real, reliable, and meaningful across multiple experiments, models, and patient samples.

Why it takes time:

  • Need to test in many samples of ovarian cancer cells called ‘cell lines’, tissue samples, or datasets.
  • Must show the results can be reproduced by others, so they are proven reliable.
  • Requires high-quality tissue samples which are often scarce, because ovarian cancer is less common than other cancers.
  • Careful and rigorous analysis is needed to show the findings are strong and reliable.

 Timeline: 2-5+ years 

Preclinical testing is the step between early lab discoveries and studies in patients. 

For treatments, this could mean testing the drug in things like lab-grown mini-tumours (organoids) and animal models to work out the safest dose, check for side effects, and understand how the drug moves through the body.  

For detection and diagnostic tests, it’s about making sure the test actually works. Researchers fine-tune the test, check how accurately it can detect what it’s meant to find, ensure it detects what it is meant to and is not confused by non-cancerous conditions, and make sure it can work in a real clinical lab. 

Why it takes time: 

  • Strict ethics approvals are needed before testing on animals or human samples.
  • Experiments must be repeated under very controlled conditions.
  • Scientists must rule out simple mistakes or hidden bias.

Timeline: 2-5+ years

If a discovery looks like it could become a real test or medicine, researchers often need to find partners to help fund it and develop it at a large scale. These partners are only likely to invest if the researcher’s work is protected through intellectual property, ensuring others can’t simply copy.

During commercialisation, universities, research institutes or hospitals work with companies (pharmaceutical companies, biotech, industry) that can help:

  • Pay for large, expensive clinical trials
  • Set up manufacturing
  • Navigate global regulations
  • Take products to market so patients can use the test or medicine

A company or organisation can agree to “sponsor” a trial, where they take responsibility for running it and paying for it.

Note: Commercialisation doesn’t always happen at the same point — it can occur early or much later, depending on the type of discovery and when industry partners see a clear path forward.

Why it take time:

  • Lawyers and technology transfer offices need to write and file patents — the documents that protect the research from others using it
  • Negotiations between universities, hospitals, and companies can take time
  • Contracts for who does what, who owns what, and how profits are shared can be complex.

Although ovarian cancer researchers share a common goal and often collaborate closely, bringing a new medicine or test to patients also requires navigating the realities of commercial funding. Without industry investment, many promising discoveries would never reach the people who need them.

 Timeline: 6 months - >3 years 

Phase I: Is it safe?

Phase I trials are small and designed to answer a single question: Is the new treatment safe? Researchers determine the safest dose and monitor side effects closely.

Why it takes time:

  • Recruiting suitable patients is careful and considered
  • Safety checks are frequent and detailed
  • Treatment doses are increased gradually throughout the trial to protect patients

Timeline: 1-3 years

Phase II: Does it work?

If the treatment appears safe, Phase II trials test whether it helps patients. Researchers look for early signs of effectiveness, often using lab imaging tools to view results taken from biopsies, and blood tests.

Why it takes time:

  • Must track responses over months or years
  • Collects large amounts of participants’ data

Timeline: 1-3 years

Phase III: Is it better than the current standard? 

Phase III trials compare the new treatment with the current standard across hundreds or thousands of patients. These studies are large, complex and expensive, and often span multiple hospitals and countries. Phase III is usually the longest trial stage.

Why it takes time:

  • Very large participant numbers
  • Coordinating many hospitals and often multiple countries is complex
  • Every site needs its own ethics approval, ensuring the trial is conducted legally and ethically, with the right consent processes
  • Huge amounts of data must be checked and analysed.
  • If the main outcome is improved survival, this takes years to measure

Timeline: 3 - 7 years

Other trial types: Basket and N-of-1  

Some newer clinical trials are designed to better match treatments to individuals.  

Basket trials test the same treatment across different cancers that share specific biological features, rather than focusing on where the cancer started.  

N-of-1 trials use precision medicine to select the treatment most likely to work for one person, based on the unique features of their cancer. 

These trials are often used when standard treatments haven’t worked, or when a cancer has features that may respond to newer targeted therapies. 

Why it takes time:

  • Each person’s cancer is different, so detailed testing is needed to choose the right treatment 
  • Finding the right biological markers can take time 
  • Treatments must be carefully checked for safety 
  • Fewer people are eligible, so recruitment can take longer 
  • Doctors need time to closely monitor how the treatment works

After something works in research, it has to be made safely and consistently in the real world. Both diagnostic tests and new treatments need to undergo manufacturing and scaling.

Why it takes time:

  • Medicines must be made in special high-standard factories so every batch is safe and identical.
  • Scaling and developing enough medicine from the tiny amount used in the lab to hundreds of thousands of doses is a major undertaking.
  • Diagnostic kits must be robust, easy to use in everyday labs, and stay stable in transport and storage.
  • Everything must work the same way, every time, for every patient.

 Timeline: 1-3 years


When a therapy or test has shown results in clinical trials, they then need to go through regulatory approval (e.g. Federal Drug Administration (FDA) in the US, Therapeutic Goods Administration (TGA) in Australia). Government regulators check all the evidence, including safety, effectiveness, side effects, and quality.

Even after approval, hospitals still need to get ready to use the new test or treatment.

This may involve:

  • Training doctors, nurses, and lab staff
  • Buying or upgrading equipment
  • Updating hospital policies and clinical guidelines
  • Building the new treatment or test into everyday care pathways

For most patients to access a new test or treatment, it must be funded by the healthcare system. Getting something listed on the Medicare Benefits Scheme (MBS) or the Pharmaceutical Benefits Scheme (PBS) takes time. The process is highly regulated and can be delayed by discussions around cost-effectiveness and complex approval pathways.

Why it matters:

  • Regulators review huge amounts of data and documents.
  • Questions often go back and forth between companies, researchers and regulators.
  • Reviews can take many months or even years.
  • Detailed economic models are built using trial data and real-world costs.
  • Companies, hospitals, and government bodies negotiate prices and conditions.

Timeline: 1-5+ years

Many tests and treatments stall here, even after they are shown to work, because of the complex factors in decision-making at this point.


All research adds pieces to the puzzle 

Scientific progress can feel slow, and true breakthroughs are rare, but each new piece of information helps researchers build a clearer and more detailed picture of how ovarian cancer works. We think of it as drops filling up the bucket. 

Even when a study doesn’t work the way scientists hoped, it’s not a failure. Knowledge is gained about what won’t work, or what to try next, to steer progress in a more promising direction.  

Re-search', a process by which we repeatedly search for possibilities, and progressively eliminate possibilities to find the answers. Not for the faint-hearted.

Professor Honami Naora

Research is now happening faster than at any other time in history, thanks to powerful new technologies:  
  • AI and machine learning can scan huge datasets to find patterns humans might miss  
  • Genomics helps researchers understand the DNA changes for each ovarian cancer subtype 
  • Spatial technologies show where each cell sits inside a tumour and how they communicate
  • Precision medicine helps to tailor treatments to each person’s unique cancer.  
  • Global data sharing and collaboration mean researchers around the world can work together, compare results, and accelerate discoveries. 

All of this means that even though research takes time, the pace of progress is accelerating, and each new discovery builds toward better detection, better treatments, and better outcomes for those with ovarian cancer. 

With the advance of genomics, with the advance of proteomics and medical imaging, we really see this tremendous coming together of minds and momentum is snowballing.

Associate Prof Simon Chu, OCRF-funded researcher at Hudson Institute of Medical Research

Funding gaps: how consistent support accelerates research

Support research like this

Science moves fastest when research teams have the resources and time to think big. Longer-term, more flexible funding allows scientists to plan boldly, keep their talented teams together, and turn today’s ideas into tomorrow’s breakthroughs. 

Every grant—whether from focused funders like the OCRF or large government programs—plays a vital role in pushing discoveries forward. Philanthropic support often fills key gaps, keeping research alive between major grants and helping high-potential ideas get off the ground. 

Researchers commonly spend a significant proportion of time away from their lab benches working on grant proposals to keep funds coming in to support the costs of experiments and staff salaries for research teams. 

OCRF is committed to reducing this burden through streamlining its own programs and advocating for a more stable and diverse funding ecosystem, to give researchers the confidence to focus on exploring, experimenting, and innovating instead of constantly chasing the next grant.  

This is vital to create the conditions where scientific progress thrives—and breakthroughs happen faster. 

 

 

Your consistent donor support makes such a significant difference. It gives researchers the stability to plan ahead, keep their teams together, and push discoveries forward faster. 

Support research like this

LEARN MORE ABOUT HOW MEDICAL RESEARCH REALLY WORKS

Explore our All Over It articles to cut through the noise and learn how real medical research works — from early discovery to clinical trials. Understand what’s proven, what’s not, and why evidence matters.

Sign up to our newsletter to learn more about OCRF-funded research, and other opportunities to learn in 2026 including webinars. 
 
Donations to support ovarian cancer research are always needed and welcome – find out how you can support the OCRF.

Sign up to OCRF newsletter
Support Ovarian Cancer Research
Get the latest news, stories & updates.
Sign up to our newsletter
The Ovarian Cancer Research Foundation acknowledges the Traditional Custodians of the lands upon which we work, strive, and learn, the Wurrundjiri Woi wurrung and Bunorung Boon wurrung peoples of the Kulin Nation. We pay our respects to Elders past and present, and extend this respect to all Aboriginal and Torres Strait Islander peoples in Australia and beyond.